265 related articles for article (PubMed ID: 37599324)
21. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
[TBL] [Abstract][Full Text] [Related]
22. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.
Evrard C; Messina S; Sefrioui D; Frouin É; Auriault ML; Chautard R; Zaanan A; Jaffrelot M; De La Fouchardière C; Aparicio T; Coriat R; Godet J; Silvain C; Randrian V; Sabourin JC; Guimbaud R; Miquelestorena-Standley E; Lecomte T; Moulin V; Karayan-Tapon L; Tachon G; Tougeron D
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457245
[TBL] [Abstract][Full Text] [Related]
24. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS
Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649
[TBL] [Abstract][Full Text] [Related]
25. Accuracy of four mononucleotide-repeat markers for the identification of DNA mismatch-repair deficiency in solid tumors.
Takehara Y; Nagasaka T; Nyuya A; Haruma T; Haraga J; Mori Y; Nakamura K; Fujiwara T; Boland CR; Goel A
J Transl Med; 2018 Jan; 16(1):5. PubMed ID: 29329588
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting.
Malapelle U; Parente P; Pepe F; De Luca C; Pisapia P; Sgariglia R; Nacchio M; Gragnano G; Russo G; Conticelli F; Bellevicine C; Vigliar E; Iaccarino A; Covelli C; Balistreri M; Clemente C; Perrone G; Danza A; Scaramuzzi F; Fassan M; Troncone G; Graziano P
Cells; 2021 Jul; 10(8):. PubMed ID: 34440647
[TBL] [Abstract][Full Text] [Related]
27. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
28. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
[TBL] [Abstract][Full Text] [Related]
29. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
[TBL] [Abstract][Full Text] [Related]
30. Precision medicine becomes reality-tumor type-agnostic therapy.
Yan L; Zhang W
Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
[TBL] [Abstract][Full Text] [Related]
31. Envafolimab - first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors.
Chen M; Jiang M; Wang X; Shen L; Li J
Expert Opin Biol Ther; 2022 Oct; 22(10):1227-1232. PubMed ID: 36124972
[TBL] [Abstract][Full Text] [Related]
32. Impact of Institutional Universal Microsatellite-Instability (MSI) Reflex Testing on Molecular Profiling Differences Between Younger and Older Patients with Colorectal Cancer.
Altshuler E; Franke AJ; Skelton WP; Feely M; Wang Y; Lee JH; Read T; Terracina K; Lou XY; Dai Y; George TJ
Clin Colorectal Cancer; 2023 Mar; 22(1):153-159. PubMed ID: 36319582
[TBL] [Abstract][Full Text] [Related]
33. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition.
Ebi H; Bando H; Taniguchi H; Sunakawa Y; Okugawa Y; Hatanaka Y; Hosoda W; Kumamoto K; Nakatani K; Yamazaki K
Cancer Sci; 2020 Oct; 111(10):3962-3969. PubMed ID: 32667108
[TBL] [Abstract][Full Text] [Related]
34. Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors.
Hollebecque A; Chung HC; de Miguel MJ; Italiano A; Machiels JP; Lin CC; Dhani NC; Peeters M; Moreno V; Su WC; Chow KH; Galvao VR; Carlsen M; Yu D; Szpurka AM; Zhao Y; Schmidt SL; Gandhi L; Xu X; Bang YJ
Clin Cancer Res; 2021 Dec; 27(23):6393-6404. PubMed ID: 34465599
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
Front Immunol; 2022; 13():913483. PubMed ID: 35958603
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
37. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
Front Immunol; 2022; 13():795972. PubMed ID: 35371084
[TBL] [Abstract][Full Text] [Related]
39. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T
Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.
Maio M; Ascierto PA; Manzyuk L; Motola-Kuba D; Penel N; Cassier PA; Bariani GM; De Jesus Acosta A; Doi T; Longo F; Miller WH; Oh DY; Gottfried M; Xu L; Jin F; Norwood K; Marabelle A
Ann Oncol; 2022 Sep; 33(9):929-938. PubMed ID: 35680043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
